Hoffmann J - Search Results

1

Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing.

Behrens D, Pfohl U, Conrad T, Becker M, Brzezicha B, Büttner B, Wagner S, Hallas C, Lawlor R, Khazak V, Linnebacher M, Wartmann T, Fichtner I, Hoffmann J, Dahlmann M, Walther W. Behrens D, et al. Among authors: hoffmann j. Cancers (Basel). 2023 Dec 8;15(24):5753. doi: 10.3390/cancers15245753. Cancers (Basel). 2023. PMID: 38136299 Free PMC article.

2

[Measurement of bromsulfalein retention in the mouse as a possible parameter for assessment of liver function after administration of liposomal preparations].

Hoffmann J, Fichtner I, Becker M, Lemm M. Hoffmann J, et al. Pharmazie. 1991 Mar;46(3):222-3. Pharmazie. 1991. PMID: 1881948 German. No abstract available.

3

Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.

Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M. Fichtner I, et al. Among authors: hoffmann j. Anticancer Res. 1994 Sep-Oct;14(5A):1995-2003. Anticancer Res. 1994. PMID: 7847840

4

Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.

Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I. Hoffmann J, et al. Clin Cancer Res. 1999 Aug;5(8):2198-204. Clin Cancer Res. 1999. PMID: 10473106

5

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Fichtner I, et al. Among authors: hoffmann j. Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138. Clin Cancer Res. 2008. PMID: 18927285 Free article.

6

Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.

Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J. Hammer S, et al. Among authors: hoffmann j. Clin Cancer Res. 2010 Mar 1;16(5):1452-65. doi: 10.1158/1078-0432.CCR-09-2455. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179216

7

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.

Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, Fichtner I. Klinghammer K, et al. Among authors: hoffmann j. Int J Cancer. 2015 Jun 15;136(12):2940-8. doi: 10.1002/ijc.29344. Epub 2014 Nov 26. Int J Cancer. 2015. PMID: 25404014 Free article.

8

Predictive In Vivo Models for Oncology.

Behrens D, Rolff J, Hoffmann J. Behrens D, et al. Among authors: hoffmann j. Handb Exp Pharmacol. 2016;232:203-21. doi: 10.1007/164_2015_29. Handb Exp Pharmacol. 2016. PMID: 26489829 Review.

9

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.

Rolff J, Becker M, Merk J, Hoffmann J, Fichtner I. Rolff J, et al. Among authors: hoffmann j. Target Oncol. 2016 Aug;11(4):507-14. doi: 10.1007/s11523-015-0415-4. Target Oncol. 2016. PMID: 26817645

10

Choosing wisely - Preclinical test models in the era of precision medicine.

Klinghammer K, Walther W, Hoffmann J. Klinghammer K, et al. Among authors: hoffmann j. Cancer Treat Rev. 2017 Apr;55:36-45. doi: 10.1016/j.ctrv.2017.02.009. Epub 2017 Mar 6. Cancer Treat Rev. 2017. PMID: 28314175 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,544 results

Search Page